The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALEC | -77.56% | -89.28% | -36.02% | -92% |
| S&P | +14.08% | +93.57% | +14.12% | +153% |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
There has been a major shakeup in the C-suite.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.26M | -78.8% |
| Gross Profit | $0.93M | -92.9% |
| Gross Margin | 28.47% | -57.3% |
| Market Cap | $299.59M | -33.9% |
| Market Cap / Employee | $1.84M | 0.0% |
| Employees | 163 | 0.0% |
| Net Income | -$34.67M | 17.9% |
| EBITDA | -$35.38M | 23.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $76.50M | 105.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $28.90M | 11.3% |
| Short Term Debt | $8.98M | 3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.31% | 1.3% |
| Return On Invested Capital | -55.70% | -5.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.52M | 36.2% |
| Operating Free Cash Flow | -$32.51M | 35.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.56 | 0.96 | 1.48 | 4.21 | 39.75% |
| Price to Sales | 1.85 | 1.38 | 1.73 | 4.40 | -40.47% |
| Price to Tangible Book Value | 1.56 | 0.96 | 1.48 | 4.21 | 39.74% |
| Enterprise Value to EBITDA | 62.39 | 4.72 | 4.12 | -1.43 | 106.89% |
| Return on Equity | -91.2% | -90.3% | -104.0% | -122.0% | 8.38% |
| Total Debt | $42.52M | $41.05M | $39.48M | $37.88M | 9.34% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
